Clinical Trials

    Showing 1 - 10 of 16 Lung Cancers

    A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (HARMONi-3)

    Status: Enrolling

    Investigator: Jun Zhang

    Study Coordinator: Gabrielle Hayes

    Phone: 734.415.918

    This is a Phase 3 Randomized, Controlled, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer. The primary endpoi... Read more >

    A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)

    Status: Enrolling

    Investigator: Jun Zhang

    Study Coordinator: Derek Cole

    Phone: 713.441.5607

    The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G1... Read more >

    A151216 - Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery ALCHEMIST

    Status: Open Not Enrolling

    Investigator: Jun Zhang

    Study Coordinator: Gabrielle Hayes

    Phone: 734.415.918

    This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for ... Read more >

    Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers

    Status: Open Not Enrolling

    Investigator: Jun Zhang

    Study Coordinator: Gabrielle Hayes

    Phone: 734.415.918

    This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ... Read more >

    Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

    Status: Enrolling

    Investigator: Jun Zhang

    Study Coordinator: Gabrielle Hayes

    Phone: 734.415.918

    This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer... Read more >

    Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients

    Status: Open Not Enrolling

    Investigator: Jun Zhang

    Study Coordinator: Gabrielle Hayes

    Phone: 734.415.918

    This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0)... Read more >

    EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker

    Status: Open Not Enrolling

    Investigator: Sindhu Nair

    Study Coordinator: Gabrielle Hayes

    Phone: 734.415.918

    This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin... Read more >

    Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

    Status: Open Not Enrolling

    Investigator: Jun Zhang

    Study Coordinator: Derek Cole

    Phone: 713.441.5607

    This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as p... Read more >

    NRG-LU005

    Status: Open Not Enrolling

    Investigator: Jun Zhang

    Study Coordinator: Gabrielle Hayes

    Phone: 734.415.918

    The study is an open-label, randomized, phase III trial to evaluate the addition of atezolizumab to standard chemoradiation for limited stage small cell lung cancer. Patients will be enrolled and randomized 1:1 between chemoradiation + atezolizumab (... Read more >

    Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    Status: Enrolling

    Investigator: Jun Zhang

    Study Coordinator: Gabrielle Hayes

    Phone: 734.415.918

    This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene calle... Read more >

    Phase I Trial Evaluating the Safety of the Dietary Supplement Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

    Status: Enrolling

    Investigator: Jun Zhang

    Study Coordinator: Derek Cole

    Phone: 713.441.5607

    The goal of this research study is to find the highest, safest dose of honokiol (a type of dietary supplement) that can be given to patients who have resectable early-stage NSCLC. Researchers also want to learn if giving honokiol before surgery can... Read more >

    Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair

    Status: Open Not Enrolling

    Investigator: Jun Zhang

    Study Coordinator: Derek Cole

    Phone: 713.441.5607

    The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), class... Read more >

    Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

    Status: Open Not Enrolling

    Investigator: Chinemerem Abanonu

    Study Coordinator: Frances Saubon

    Phone: 713.624.0724

    This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (re... Read more >

    Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

    Status: Open Not Enrolling

    Investigator: Jun Zhang

    Study Coordinator: Gabrielle Hayes

    Phone: 734.415.918

    This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the gr... Read more >

    Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC)

    Status: Open Not Enrolling

    Investigator: Jun Zhang

    Study Coordinator: Gabrielle Hayes

    Phone: 734.415.918

    The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tum... Read more >

    Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adults With Untreated Metastatic Non-Squamous (NSCLC)

    Status: Enrolling

    Investigator: Jun Zhang

    Study Coordinator: Gabrielle Hayes

    Phone: 734.415.918

    Livmoniplimab is an investigational drug being developed for the treatment of NSCLC. There are 2 stages to this study. In Stage 1, there are 4 treatment arms. Participants will either receive livmoniplimab (at different doses) in combination with bud... Read more >